Affimed (AFMD) Competitors $1.04 +0.02 (+1.96%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.02 -0.02 (-2.21%) As of 02/21/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AFMD vs. ME, HOWL, IPSC, AADI, STTK, CTMX, VHAQ, CNTX, QNCX, and KRONShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include 23andMe (ME), Werewolf Therapeutics (HOWL), Century Therapeutics (IPSC), Aadi Bioscience (AADI), Shattuck Labs (STTK), CytomX Therapeutics (CTMX), Viveon Health Acquisition (VHAQ), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Affimed vs. 23andMe Werewolf Therapeutics Century Therapeutics Aadi Bioscience Shattuck Labs CytomX Therapeutics Viveon Health Acquisition Context Therapeutics Quince Therapeutics Kronos Bio 23andMe (NASDAQ:ME) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking. Which has more volatility & risk, ME or AFMD? 23andMe has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Do insiders & institutionals believe in ME or AFMD? 36.1% of 23andMe shares are owned by institutional investors. Comparatively, 30.8% of Affimed shares are owned by institutional investors. 26.3% of 23andMe shares are owned by company insiders. Comparatively, 3.8% of Affimed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer ME or AFMD? 23andMe presently has a consensus price target of $9.40, suggesting a potential upside of 288.43%. Affimed has a consensus price target of $13.50, suggesting a potential upside of 1,198.08%. Given Affimed's stronger consensus rating and higher probable upside, analysts clearly believe Affimed is more favorable than 23andMe.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 23andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the MarketBeat Community favor ME or AFMD? Affimed received 427 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 70.24% of users gave Affimed an outperform vote while only 50.00% of users gave 23andMe an outperform vote. CompanyUnderperformOutperform23andMeOutperform Votes1250.00% Underperform Votes1250.00% AffimedOutperform Votes43970.24% Underperform Votes18629.76% Does the media prefer ME or AFMD? In the previous week, 23andMe had 6 more articles in the media than Affimed. MarketBeat recorded 6 mentions for 23andMe and 0 mentions for Affimed. Affimed's average media sentiment score of 0.00 beat 23andMe's score of -0.24 indicating that Affimed is being referred to more favorably in the news media. Company Overall Sentiment 23andMe Neutral Affimed Neutral Is ME or AFMD more profitable? 23andMe has a net margin of -183.39% compared to Affimed's net margin of -7,836.26%. 23andMe's return on equity of -170.07% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets 23andMe-183.39% -170.07% -62.13% Affimed -7,836.26%-193.84%-107.24% Which has stronger earnings & valuation, ME or AFMD? Affimed has lower revenue, but higher earnings than 23andMe. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio23andMe$219.64M0.30-$666.70M-$15.45-0.16Affimed$8.95M1.87-$114.66MN/AN/A SummaryAffimed beats 23andMe on 9 of the 16 factors compared between the two stocks. Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.74M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / Sales1.87309.83453.2580.30Price / CashN/A67.8344.0437.47Price / Book0.256.747.634.64Net Income-$114.66M$138.11M$3.18B$245.69M7 Day Performance-1.89%-2.43%-1.91%-2.66%1 Month Performance-5.45%-1.91%-0.19%-2.15%1 Year Performance-80.49%-5.03%16.70%12.90% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed4.0782 of 5 stars$1.04+2.0%$13.50+1,198.1%-80.2%$16.74M$8.95M0.00200ME23andMe1.3638 of 5 stars$2.55+3.2%$9.40+268.6%-81.9%$66.60M$208.78M-0.17770Analyst ForecastNews CoverageHOWLWerewolf Therapeutics2.1919 of 5 stars$1.49-1.3%$9.33+526.4%-79.2%$66.40M$3.39M-0.9740IPSCCentury Therapeutics2.3755 of 5 stars$0.77+2.8%$10.00+1,191.2%-82.5%$65.86M$2.68M-0.42170AADIAadi Bioscience0.7882 of 5 stars$2.59-0.8%$1.67-35.6%+49.2%$63.97M$25.07M-1.1440STTKShattuck Labs3.5411 of 5 stars$1.33+6.4%$8.67+551.6%-84.4%$63.49M$1.66M-0.87100News CoverageCTMXCytomX Therapeutics4.3403 of 5 stars$0.80-3.6%$5.77+624.9%-46.2%$62.32M$101.21M4.68170Positive NewsVHAQViveon Health AcquisitionN/A$11.00flatN/A+1.8%$62.26MN/A0.002High Trading VolumeCNTXContext Therapeutics1.2627 of 5 stars$0.82+1.9%$6.33+670.9%-32.6%$61.62MN/A-0.907News CoverageGap UpQNCXQuince Therapeutics2.1336 of 5 stars$1.40-1.4%$9.50+578.6%+4.5%$61.60MN/A-1.1360KRONKronos Bio3.4407 of 5 stars$1.02flat$1.63+59.3%-5.0%$61.55M$6.29M-0.71100Positive News Related Companies and Tools Related Companies ME Competitors HOWL Competitors IPSC Competitors AADI Competitors STTK Competitors CTMX Competitors VHAQ Competitors CNTX Competitors QNCX Competitors KRON Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AFMD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AFMD Stock Alerts